AURA BIOSCIENCES, INC. (AURA)
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
📈 **POSITIVE** • High confidence analysis (93%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical